IMUGENE LIMITED - News & Media

Market Cap $386.7M Add to my watchlist

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

No News & Media currently available.

(20min delay)
Last 3.7¢		Change 0.000(0.00%)		Mkt cap ! $386.7M

Open	High	Low	Value	Volume
3.6¢	3.8¢	3.5¢	$674.7K	18.62M

Buyers (Bids)

No.	Vol.	Price($)
2	58954	3.7¢

Sellers (Offers)

Price($)	Vol.	No.
3.8¢	1948252	15

View Market Depth

No.	Vol.	Price($)
18	5665336	0.018
14	3997559	0.017
6	2974375	0.016
10	3219799	0.015
4	497500	0.014

Price($)	Vol.	No.
0.019	400000	2
0.020	5410946	12
0.021	8494780	17
0.022	8757253	13
0.023	4826614	8

Last trade - 12.59pm 22/11/2024 (20 minute delay)


Last 3.8¢		Change 0.000 ( 1.35 %)
Open	High	Low	Volume
3.6¢	3.8¢	3.6¢	8274602
Last updated 13.10pm 22/11/2024 ?

IMU (ASX) Chart